| TAH Drug Code | IORG |
|---|---|
| Indications | For the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation. |
| Dosing | 250 mcg once daily during the mid-to-late phase after initiating follicle-stimulating hormone on day 2 or 3 of cycle. Treatment should be continued daily until the day of chorionic gonadotropin administration. |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Known hypersensitivity to Ganirelix Acetate or to any of its components. Known hypersensitivity to GnRH or any other GnRH analog. Known or suspected pregnancy. |
| Adverse Effects | Common Neurologic: Headache (3% ) Reproductive: Abdominal pain, Gynecological (4.8% ), Vaginal bleeding (1.8% ) Serious Immunologic: Hypersensitivity reaction Reproductive: Ovarian hyperstimulation syndrome (2.4% ) Other: Undelivered in utero fetal death (3.7% ) |
| Pregnancy | Unknown |
| Lactation | Unknown |
| More Info | UpToDate |